Skip to content
Peptide research

Thymagen

Also known as Thymogen · EW Dipeptide
Category
Bioregulators
Administration routes
InjectableNasal
Regulatory status
Not FDA-approved

A dipeptide (Glu-Trp) marketed for immune restoration and healthy aging by acting on T lymphocytes and thymic tissue. Immune-restoration evidence remains limited. Anti-aging is supported by animal work, while Western IM862 oncology trials provide human safety and efficacy data but did not establish cancer benefit. Those trials do not establish safety for healthy-aging use. Effects on tumor biology and hormone pathways remain theoretical concerns. It is not an approved drug in the US, and products sold online are unregulated.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Thymagen (also known as Thymogen) is a synthetic 2-amino-acid peptide originally isolated from Thymalin, a thymus gland extract. Developed by Professor Vladimir Khavinson in Russia and registered as a pharmaceutical in the USSR in 1990, it is one of the earliest Khavinson bioregulatory peptides. Thymagen is designed to support immune function by enhancing T-cell development and reducing inflammation. Interestingly, its mirror-image form (made with D-amino acids) has the opposite effect — suppressing rather than stimulating immunity — and was developed as the separate drug Thymodepressin.

How it works in the body

A dipeptide bioregulator (Glu-Trp) that targets T lymphocytes and thymic epithelial cells. It modulates T cell differentiation by interacting with regulatory elements in genes controlling CD4/CD8 ratios, cytokine production, and the maturation of naive T cells into functional effector cells.

Research overview

Thymagen works primarily by activating T-cell development and maturation, enhancing the immune system's ability to recognize and respond to threats. It also boosts B-cell activity and the germ-killing capacity of neutrophils, while dramatically reducing the inflammatory signal TNF-alpha (by roughly five-fold in lab models). In animal studies, it increased mean lifespan of the longest-lived 10% by about 10%, without increasing overall mean lifespan, and reduced spontaneous cancer rates, cutting blood cancers by 3.4-fold. Clinical studies in Russia report a 94.4% response rate in type 1 diabetes patients with weakened immunity. Approximately 50-80 publications reference Thymagen directly, though most originate from Russian research groups. Western human trials were registered as IM862/oglufanide, including the randomized placebo-controlled trial NCT00002445.

Who researches Thymagen?

Commonly researched by

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

  • People researching liver health

    Studied for hepatoprotective effects or liver function support.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Not recommended for children outside the indications on the Russian label; not approved in the US.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Limited Western clinical safety data

    High

    PMID 15598977; https://clinicaltrials.gov/study/NCT00002445

  • Potential immune over-activation

    Theoretical

    PMID 12845648; PMID 35408963

  • Endocrine interactions

    Theoretical

    PMID 15495616; PMID 19140517

  • Research-grade product quality concerns (US market)

    High

    PMID 38732260; PMID 10217204

  • Unknown long-term effects of chronic use

    Moderate

    PMID 21957588; PMID 11707921

  • Potential effects on tumor biology

    Moderate

    PMID 15598977; PMID 12845648

Interaction summary(8)

Rated by direction with this peptide

  • Active Kaposi's sarcoma / antiretroviral therapy context

    CautionModerate

    In a 202-patient phase III randomized placebo-controlled trial, the same molecule (IM862) given alongside antiretroviral therapy showed no benefit over placebo (response 23% vs 21%, p=0.46) and a significantly shorter median time to tumor progression (16 vs 35 weeks, p=0.012), so combining it with HAART in a patient with active KS has direct human evidence of potential harm.

    PMID 15598977; https://clinicaltrials.gov/study/NCT00002445

  • Immunosuppressants (cyclosporine, tacrolimus, azathioprine, mycophenolate)

    CautionTheoretical

    Direct pharmacodynamic opposition - Thymogen's stated purpose is T-cell activation and CD4/CD8 normalization, which works against the therapeutic goal in transplant or autoimmune immunosuppression; no interaction study exists, but the mechanistic conflict is unambiguous and the D-isomer of the same dipeptide is marketed precisely as an immunosuppressant.

    PMID 38732260

  • Systemic corticosteroids

    CautionTheoretical

    Glucocorticoids are thymolytic and suppress T-cell maturation, plausibly blunting Thymogen's thymic-epithelial and T-differentiation effects while Thymogen may partially counteract intended steroid immunosuppression; no clinical interaction data exist in either direction.

    Mechanism-based (no interaction study identified)

  • Antifungal therapy (nystatin, azoles) in candidiasis

    SynergisticLow

    Thymogen was used as an immunocorrector adjunct to lymphotropic antifungal therapy in 52 patients with oral mucosal candidiasis with normalized mucosa and reduced yeast colonization, and cleared fungal infection in an immunodepressed animal model, though the uncontrolled designs cannot separate the peptide's contribution from the antifungal.

    PMID 8992656; PMID 2337388

  • Standard anti-tuberculosis chemotherapy

    SynergisticLow

    In destructive pulmonary tuberculosis, Thymogen added to anti-TB regimens reportedly stimulated the T-cell link, improved tolerance to anti-TB drugs, and accelerated cavity healing and sputum conversion (open-label Russian data only).

    PMID 10605346; PMID 10067345

  • Interferon inducers (e.g., cycloferon)

    SynergisticLow

    Combined cycloferon plus Thymogen normalized immune-status parameters and was associated with a more favorable postoperative course in uterine cancer surgery, consistent with reviews classifying thymic dipeptides among interferon-inducing immunomodulators; evidence is observational, not randomized.

    PMID 16786663; PMID 19355963

  • Thyroid medications (levothyroxine, thiamazole/mercazolyl)

    SynergisticTheoretical

    Thyroid status modulates the response - in experimental hypothyroidism the immunotropic effect of immunomodulators including Thymogen was substantially greater once thyroid function was compensated, and Thymogen altered L-thyroxine-associated brain water content in a rat toxic-edema model; direction is favorable in these animal models but no human data exist, so treat thyroid-replaced patients as an untested population rather than an established synergy.

    PMID 15495616; PMID 19140517

  • ACE inhibitors and antihypertensives

    CautionTheoretical

    Glu-Trp (EW) itself showed measurable ACE-inhibitory activity in human umbilical vein endothelial cells and blocked angiotensin I-induced vasoconstriction in rat aorta, raising a theoretical additive blood-pressure-lowering effect; EW was less potent than Ile-Trp and no in-vivo blood pressure effect was demonstrated for EW specifically.

    PMID 28102435

Known risks(6)

  • Limited Western clinical safety data

    Moderate

    While Thymogen has been used as a registered pharmaceutical in Russia since 1990 with reports of minimal side effects, the safety data has not been independently validated through Western regulatory processes. Russian clinical reports state that 'thymalin and thymogen have practically no side effects,' but this has not been confirmed in large, well-controlled studies meeting FDA or EMA standards.

  • Potential immune over-activation

    Moderate

    As an immunostimulant, Thymagen could theoretically exacerbate autoimmune conditions by enhancing T-cell differentiation and immune cell activation. Individuals with autoimmune diseases, organ transplants, or other conditions requiring immunosuppression should exercise extreme caution.

  • Endocrine interactions

    Low-Moderate

    Russian pharmaceutical literature notes relative contraindications including the perimenstrual period, pituitary adenoma, acromegaly, and use during the period of physiological thymic activity up to puberty. Synergistic effects have been noted with pituitary hormones (somatotropin, luteinizing hormone) and estrogens.

  • Research-grade product quality concerns (US market)

    Moderate

    In the US, Thymagen is sold only as unregulated products online. Unregulated products sold online lack pharmaceutical-grade quality controls, sterility assurance, and endotoxin testing required for injectable medications. Self-administration carries infection and contamination risks.

  • Unknown long-term effects of chronic use

    The longest controlled study (Anisimov & Khavinson 2001) treated rats for 12 months, showing anti-aging benefits. However, long-term effects of chronic Thymagen use in humans are not well-characterized. Effects on immune homeostasis, cancer surveillance, and endocrine function over years of use remain unknown.

  • Potential effects on tumor biology

    Low (potentially beneficial)

    Preclinical data shows Thymagen reduces spontaneous carcinogenesis and inhibits tumor growth via NK cell activation. However, as an immune modulator that affects cell proliferation and cytokine networks, effects on pre-existing cancers or cancer subtypes not mediated by NK cells are unpredictable.

Drug interactions(6)

  • Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids)

    Theoretical antagonistic interaction. Thymagen stimulates T-cell differentiation and immune activation, which directly opposes the mechanism of immunosuppressive drugs. Combined use could reduce immunosuppressant efficacy and increase transplant rejection risk. Contraindicated in organ transplant recipients.

  • Pituitary hormones (somatotropin, luteinizing hormone) and estrogens

    Documented synergistic effects. Russian pharmaceutical literature reports that thymic peptide bioregulators have synergistic interactions with pituitary gland hormones and estrogens, potentially amplifying both immune and endocrine effects. Combined use may require dose adjustment.

  • Sex hormones (progestins, androgens) and adrenal corticosteroids

    Documented antagonistic effects. Russian literature notes that progestins, androgens, and adrenal hormones act as antagonists to thymic peptide bioregulators, potentially reducing Thymagen's immunostimulatory efficacy.

  • Other immunostimulants (interferons, interleukins, colony-stimulating factors)

    Theoretical additive immune stimulation. Combining Thymagen with other immunostimulatory agents could produce excessive immune activation. The 2003 knockout mouse study showed Thymagen's activity is partly IL-12-dependent, suggesting potential interaction with IL-12-based therapies.

  • Cancer immunotherapies (checkpoint inhibitors, CAR-T)

    Theoretical — unknown interaction profile. Thymagen enhances NK cell cytolytic activity and T-cell function, which could theoretically augment or complicate immunotherapy responses. No clinical data available. Use with cancer immunotherapies should only be considered under strict medical supervision.

  • Anti-coagulants and fibrinolytics

    Theoretical interaction. Thymalin-derived peptides (including Thymagen/EW) have been reported to normalize coagulation and fibrinolytic activity. Combined use with anticoagulants (warfarin, heparin, DOACs) could theoretically affect bleeding risk. No direct clinical data.

Research & benefits

Evidence base

Evidence Level
Mostly Preclinical
Total Studies
65
Human Studies
8

Thymagen's clinical evidence is limited and comes almost entirely from Russian clinical studies published in Russian-language journals between 1990-2015. A clinical study in type 1 diabetes patients showed a 94.4% clinical response rate for immunocorrection. Additional clinical experience includes treatment of candidiasis, inflammatory gynecological diseases, and viral infections. In Russia, Thymogen has been used clinically since 1990 as a registered pharmaceutical. None of these studies have been replicated in large, randomized, double-blind Western clinical trials, and the evidence has not been independently validated outside of the Russian research ecosystem. Human evidence also includes a 202-patient Western placebo-controlled phase III trial of IM862/oglufanide that found no superiority in AIDS-related Kaposi sarcoma and possible earlier progression; the Russian surgical trial addresses a different indication. The cited longevity study was in rats; reproducibility and human benefit are not established.

Researched for(8)

Rated by confidence in the evidence

  • Immune system restoration and T-cell activation

    Medium

    Multiple human studies, including one placebo-controlled trial, show T-cell restoration across conditions.

    PMID 21957588; PMID 10605346; PMID 12506630; PMID 12918362

  • Anti-aging and lifespan extension

    Low

    Single rat study showed longer maximum lifespan, not yet tested in humans.

    PMID 11707921; PMID 24003726

  • Anti-tumor activity and reduced spontaneous carcinogenesis

    Low

    Reduced tumor incidence in rats, but the same dipeptide failed in several human cancer trials.

    PMID 11707921; PMID 12845648; PMID 15598977 (NCT00002445); PMID 15354209; NCT00006037; NCT00017303

  • Anti-inflammatory and TNF-alpha suppression

    Speculative

    Based on one lab-dish study, with no animal or human inflammation data yet.

    PMID 35408963

  • Immunocorrection in secondary immunodeficiency (type 1 diabetes)

    Speculative

    One small uncontrolled study in diabetics reported high response rates, unreplicated and unblinded.

    PMID 9026934; PMID 15311693

  • Reduced severity of fungal infections under immunodepression

    Low

    Animal data plus one uncontrolled human case series, confounded by concurrent antifungal treatment.

    PMID 2337388; PMID 8992656

  • Perioperative immune restoration in elderly patients

    Medium

    One small randomized, placebo-controlled trial in elderly surgical patients, not independently replicated.

    PMID 21957588; PMID 16786663

  • Hepatoprotective and antioxidant effects (via analogues)

    Low

    Rat studies support liver protection, but mostly test chemical analogues, not the original peptide.

    PMID 40442470; PMID 37861903; PMID 12227096

Benefits(8)

  • Immune system restoration and T-cell activation

    Anisimov & Khavinson 2000 (Biogerontology, PMID 11707921) — Thymagen activated T-cell differentiation, T-cell recognition of peptide-MHC complexes, and neutrophilic chemotaxis and phagocytosis in rats. Smirnov et al. 2011 (PMID 21957588) — double-blind, randomized, placebo-controlled study showed thymogen restored structural and functional parameters of cellular immunity in elderly surgical patients.

  • Anti-aging and lifespan extension

    Anisimov & Khavinson 2000 (Biogerontology, PMID 11707921) — Mean lifespan of the longest-lived 10% was 949 days in controls versus 1048 days in treated rats; overall mean lifespan was unchanged. Aging rate (Gompertz alpha) was 0.0071/day in controls vs. 0.0041/day in the treated group, representing a 42% reduction in biological aging rate.

  • Anti-tumor activity and reduced spontaneous carcinogenesis

    Anisimov & Khavinson 2000 (Biogerontology, PMID 11707921) — Total tumor incidence 1.5x lower, malignant tumors 1.7x lower, hematopoietic malignancies 3.4x lower vs. controls (P < 0.02). Smith et al. 2003 (Int J Cancer, PMID 12845648) — L-Glu-L-Trp inhibited tumor growth in mice via NK cell cytolytic activity dependent on perforin and partly on IL-12.

  • Anti-inflammatory and TNF-alpha suppression

    Avolio et al. 2022 (Int J Mol Sci, PMID 35408963) — Thymogen acted as a natural inducer of TNF tolerance in monocytes and as an anti-inflammatory molecule in macrophages during LPS-mediated inflammatory activity. TNF-alpha synthesis reduced approximately five-fold in LPS-induced inflammation models.

  • Immunocorrection in secondary immunodeficiency (type 1 diabetes)

    Zhuk & Galenok 1996 (PMID 9026934) — Clinical trial in type 1 diabetes patients with secondary immunodeficiency. Thymogen removed signs of secondary immunodeficiency via activation of T-lymphocyte differentiation. Clinical effect in 94.4% of patients, laboratory improvement in 83.3%.

  • Reduced severity of fungal infections under immunodepression

    Khmel'nitskii et al. 1990 (PMID 2337388) — Thymogen injections reduced severity of candidiasis under immunodepression by activating the immunocompetent system including thymus, favoring disappearance of the fungal infection.

  • Perioperative immune restoration in elderly patients

    Smirnov et al. 2011 (PMID 21957588) — Double-blind, randomized, placebo-controlled study: intranasal Thymogen (100 mcg/day for 7 days preoperatively) in elderly patients with abdominal tumors restored cellular immunity, significantly decreased postoperative complications, and shortened the postoperative period.

  • Hepatoprotective and antioxidant effects (via analogues)

    Zhilinkova et al. 2023 (Bull Exp Biol Med) — Thymogen and its D-alanine-modified analogues suppressed oxidative peroxidation and stimulated reparative regeneration of hepatocytes in acute toxic hepatopathy models.

Key studies(5)

  1. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats

    Original research (preclinical, long-term in vivo)76 outbred female rats (44 treated, 32 controls)12 months of treatment, lifetime observation

    Anisimov VN, Khavinson VK, Morozov VG

    Biogerontology

    2000

    L-Glu-L-Trp (5 mcg/rat, SC, 5x/week for 12 months) increased mean lifespan of the longest-lived 10% from 949 to 1048 days (overall mean lifespan was unchanged), reduced Gompertz aging rate by 42%, and decreased total tumor incidence 1.5x, malignant tumors 1.7x, and hematopoietic malignancies 3.4x vs. controls. This rat study is the main basis for the dipeptide's anti-aging and anti-cancer claims.

  2. Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan

    Original research (preclinical, mechanistic)Multiple mouse cohorts including knockout modelsVarious

    Smith DL, Cai J, Zhu ST, Wei W, Fukumoto J, Sharma S, Masood R, Gill PS

    International Journal of Cancer

    2003

    L-Glu-L-Trp inhibited tumor growth in mice without direct cytotoxicity to tumor cells. Antitumor activity required NK cell perforin-dependent cytolysis and was partly dependent on IL-12 but independent of IFN-gamma. First mechanistic demonstration that Thymagen's anti-cancer effects are immune-mediated via NK/NKT cell activation.

  3. Application of Thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity

    Double-blind, randomized, placebo-controlled clinical trialElderly patients with abdominal/retroperitoneal solid tumors7 days preoperative intranasal administration (100 mcg/day)

    Smirnov VS, et al.

    Advances in Gerontology (Russian)

    2011

    Preoperative intranasal Thymogen restored structural and functional parameters of cellular immunity, led to a statistically significant decrease in the number and range of postoperative complications, and shortened the postoperative period vs. placebo. Strongest clinical evidence for Thymagen from a Western-standard study design.

  4. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

    Original research (in vitro, mechanistic)THP-1 cell line experiments with 5 Khavinson peptidesIn vitro

    Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, et al.

    International Journal of Molecular Sciences

    2022

    Thymogen and four other Khavinson peptides cooperated as natural inducers of TNF tolerance in monocytes and acted on macrophages as anti-inflammatory molecules during LPS-mediated inflammatory activity. All five peptides modulated key proliferative patterns, increasing tyrosine phosphorylation of mitogen-activated cytoplasmic kinases.

  5. Deigin V, Linkova N, Vinogradova J, et al.

    International Journal of Molecular Sciences

    2024

    Reviewed the first examples of up-and-down homeostasis regulation by two enantiomeric drugs: immunostimulant Thymogen (L-Glu-L-Trp) and immunosuppressor Thymodepressin (D-Glu-D-Trp). Reversal of both chiral centers produced reciprocal biological activity — a fundamental finding in peptide pharmacology.

Regulation & availability

Why researchers look at it

One rat study found a roughly 10% increase in mean lifespan of the longest-lived 10% (overall mean lifespan was unchanged) and a 3.4-fold reduction in spontaneous blood cancers, and a double-blind RCT in elderly surgical patients demonstrated immune restoration and reduced postoperative complications. As possibly the simplest bioactive peptide — just two amino acids — it has been a registered pharmaceutical in Russia since 1990. Independent Western trials could establish whether these animal longevity results translate to humans.

Estimated cost
$30-80/mo oral capsules
FDA status
Not FDA-approved for any indication. No current IND was publicly verified; public approval records cannot establish that an IND was never submitted. The dipeptide also underwent Western clinical investigation as IM862/oglufanide disodium. No qualifying basis for routine compounding from bulk under 503A or 503B was identified. Thymogen has been a registered pharmaceutical in the Russian Federation since 1990, approved by the Russian Ministry of Health for immunocorrection, but Russian medicinal registration does not confer U.S. approval.
WADA status
Not specifically named in the WADA 2026 Prohibited List. S0 concerns pharmacological substances without current therapeutic approval by any governmental health authority; it does not exclude Russian approvals. Russian Thymogen medicinal approval therefore contradicts an S0 rationale based on lack of approval. A compound-specific classification was not confirmed; athletes should obtain a determination from their anti-doping organization.
Prescribability
Not an FDA-approved medication in the United States. No qualifying basis for routine compounding from bulk under 503A or 503B was identified; Thymagen/Thymogen is absent from the published interim-category lists. In Russia, Thymogen has been a registered medicine since 1990, approved by the Russian Ministry of Health for correction of immune functions, with nasal and intramuscular formulations; injection is prescription-only. Western clinical trials occurred under IM862/oglufanide.
Availability
In Russia and some CIS countries, Thymogen is marketed as a registered medicine in nasal (Thymogen Spray) and intramuscular formulations. The injectable product requires a prescription; nonprescription access must not be generalized across formulations. In the United States and Western countries, Thymagen is not available as an approved pharmaceutical: no FDA-approved U.S. product or qualifying routine bulk-compounding basis was identified. Some integrative medicine clinics may offer Thymagen, but an offering does not establish approval or lawful bulk compounding. EU authorization and country-specific access exceptions require separate verification.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(12)

  1. 1970s
    Vladimir Khavinson and V.G. Morozov begin isolating peptide complexes from animal thymus glands at the Military Medical Academy in Leningrad (now St. Petersburg), initially for Soviet military research programs.
  2. 1982-1985
    Thymalin (the parent polypeptide complex) is registered as a pharmaceutical in the USSR for immunocorrection. The active dipeptide Glu-Trp is isolated from Thymalin by RP-HPLC and subsequently synthesized.
  3. 1990
    Synthetic dipeptide L-Glu-L-Trp is registered as the pharmaceutical 'Thymogen' in the USSR. Khavinson receives the USSR Council of Ministers' Prize for introducing peptide bioregulators into healthcare. Thymogen becomes one of six registered Khavinson peptide pharmaceuticals.
  4. 1990
    Khmel'nitskii et al. publish study on Thymogen's effect on immune system in candidiasis under immunodepression (PMID 2337388), part of early clinical validation.
  5. 1996
    Zhuk & Galenok publish clinical study of Thymogen in type 1 diabetes mellitus showing 94.4% clinical effect for immunocorrection (PMID 9026934).
  6. 2000
    Anisimov & Khavinson publish landmark study in Biogerontology showing L-Glu-L-Trp extends lifespan and inhibits carcinogenesis in rats (PMID 11707921). First major English-language publication establishing anti-aging properties.
  7. 2003
    Smith et al. publish mechanistic study demonstrating Thymagen's antitumor activity requires NK cell perforin-dependent cytolysis (PMID 12845648).
  8. 2011
    Smirnov et al. publish double-blind RCT of intranasal Thymogen in elderly surgical patients showing immune restoration and reduced postoperative complications (PMID 21957588).
  9. 2020
    Khavinson et al. publish proposal for using peptide bioregulators (including Thymogen) in COVID-19 complex therapy (MDPI Molecules, PMC7583759).
  10. 2022
    Avolio et al. publish study showing Thymogen acts as anti-inflammatory molecule and TNF tolerance inducer in human monocyte/macrophage cell line (PMID 35408963).
  11. 2024
    Deigin et al. publish review on reciprocal chiral activities of Thymogen (immunostimulant) and Thymodepressin (immunosuppressant) — the first characterized pair of enantiomeric peptide pharmaceuticals (PMID 38732260).
  12. 2026-present
    Thymogen remains a registered medicine in Russia, with no FDA-approved product identified. Western oncology trials were registered under IM862/oglufanide, including NCT00002445. Current IND status was not publicly verified.

Sources & FAQs

Research sources(16)

Frequently asked questions(5)

What is the difference between Thymagen, Thymalin, and Thymosin Alpha-1?

These are three distinct thymic peptides. Thymalin is a polypeptide complex (multiple peptides) extracted from calf thymus glands — it is the parent compound from which Thymagen was isolated. Thymagen (Thymogen) is a single synthetic dipeptide (Glu-Trp) identified as one of the active immunomodulatory components of Thymalin. Thymosin Alpha-1 (Ta1) is a completely different 28-amino-acid peptide originally isolated from Thymosin Fraction 5 by Allan Goldstein at George Washington University. Ta1 has much more extensive Western clinical data, including approval in over 30 countries for hepatitis B. All three modulate immunity but through different mechanisms and with vastly different levels of clinical evidence.

Has Thymagen been tested in human clinical trials?

Yes, but primarily in Russian clinical studies. A double-blind, randomized, placebo-controlled trial (Smirnov et al. 2011) tested intranasal Thymogen in elderly cancer surgery patients and showed immune restoration and reduced postoperative complications. Another study in type 1 diabetes patients showed 94.4% clinical response rate for immunocorrection. Western oncology trials were registered under IM862/oglufanide; they do not establish immune-restoration or anti-aging benefits. The clinical evidence is limited by small sample sizes and publication primarily in Russian-language journals.

How does the chirality of Thymagen affect its function?

This is one of the most fascinating aspects of Thymagen pharmacology. The natural L-form (L-Glu-L-Trp, Thymogen) is an immunostimulant — it activates T-cells, enhances immune function, and promotes immune restoration. The D-form (D-Glu-D-Trp, Thymodepressin) has the exact opposite effect: it suppresses immune function and is used as an immunosuppressive drug. This reciprocal chiral activity was described in a 2024 review by Deigin et al. (PMID 38732260) and represents a rare example of enantiomeric peptide drugs with opposing pharmacological profiles.

Is Thymagen the same as the Russian nasal spray Thymogen?

Yes, they are the same molecule. The Russian nasal spray formulation (Thymogen Spray) delivers the same Glu-Trp dipeptide intranasally.

Can Thymagen help with COVID-19 or other viral infections?

Russian researchers have proposed that Thymagen and its parent compound Thymalin could be effective in complex therapy for COVID-19 (Khavinson et al. 2020, MDPI Molecules). The rationale is that immunoprotective peptides may help prevent the 'cytokine storm' seen in severe COVID-19 by regulating immune homeostasis rather than simply suppressing or stimulating immunity. Thymalin has been used in Russia for pneumonia of various etiologies, and its component peptides (including Thymagen/EW) normalize coagulation and fibrinolytic activity. However, no controlled clinical trials have specifically tested Thymagen for COVID-19 or any other viral infection in a Western regulatory framework.